Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab versus placebo as second-line treatment after sorafenib for hepatocellular carcinoma
NL-OMON37858Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Ramucirumab + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: overall survival. Started Jun 2012; status: active, not recruiting.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON37858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37858.